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Besides	malignant	 cells,	 tumours	 are	 composed	 of	 vascular,	 hematopoietic	 and	
mesenchymal	cells,	amongst	which	in	particular	macrophages	can	be	found	numer-
ously	within	the	tumour	infiltrate.	So	called	tumour-associated	macro	phages	(TAM)	
exert	 important	 tumour-supportive	roles	and	are	 involved	 in	tumour	 initiation,	








In	 the	past	 years,	 our	 group	has	 identified	Ms4a8a,	 Stabilin-1	 and	Lyve-1	 as	





















Functional	 analyses	 were	 accomplished	 using	 genetically	 engineered	 Lyve-1	









a	 me	talloproteinase	 mediated	 shedding	 process	 in	 macrophages	 and	 endothe-
lial	cells	in	a	comparable	fashion.	To	address	our	hypothesis	that	sLyve-1	might	
function	as	a	decoy	receptor,	we	incubated	melanoma	cell	lines	with	macrophage	
derived	 and	 synthetic	 sLyve-1	 and	 observed	 reduced	 tumour	 cell	 proliferation.	
Physiological	 relevance	of	Lyve-1	 shedding	was	demonstrated	by	 the	quantifica-
tion	of	sLyve-1	in	human	plasma.	The	concentration	of	sLyve-1	was	significantly	
increased	in	plasma	samples	derived	from	psoriasis	patients.
To	 examine	 the	 relevance	 of	 Lyve-1+	 macrophages	 for	 tumour	 growth	 we	
injected	 B16	melanoma	 tumour	 cells	 subcutaneously	 into	 the	 flank	 of	 Lyve-1-/-	
mice.	After	ten	days	enhanced	tumour	growth	due	to	increased	tumour	cell	pro-
liferation	was	observed	in	the	knockout	mice	in	comparison	to	wild	type	controls.	








Tumore	 sind	 komplexe	 organ-ähnliche	 Strukturen,	 die	 neben	malignen	 Zellen	
von	vaskulären,	hämatopoetischen	und	mesenchymalen	Zellen	gebildet	werden,	
wobei	insbesondere	Makrophagen	zahlreich	im	Tumorinfiltrat	zu	finden	sind.	So	
genannte	 Tumor-assoziierte	Makrophagen	 (TAM)	 führen	 wichtige	 tumor-unter-
stützende	 Funktionen	 aus.	 Als	Quelle	 von	 angiogenen,	 anti-inflammatorischen	
und	Matrix-umbauenden	Faktoren	beeinflussen	TAM	maßgeblich	die	Tumoriniti-








In	den	 letzten	 Jahren	hat	unsere	Gruppe	Ms4a8a,	 Stablilin-1	und	Lyve-1	 als	
neue	Marker	für	murine	TAM	identifiziert.	Die	Expression	von	Lyve-1	konnte	in 
vitro	 in	Knochenmarkmakrophagen	durch	die	 Stimulation	mit	 Tumor-konditio-
niertem	Medium,	Dexamethason	und	IL-4	induziert	werden.	Das	Hauptziel	der	
vorliegenden	Arbeit	war	es	die	Expression	und	die	Prozessierung	von	Lyve-1	in	

























Adhäsionsassays	 konnten	 wir	 Fibronektin	 als	 weiteren	 Bindungspartner	 von	
Lyve-1	identifizieren.	
In	 Analogie	 zu	 CD44,	 dessen	 Ectodomäne	 proteolytisch	 abgespalten	 wird,	
konnten	wir	eine	lösliche	Form	von	Lyve-1	(sLyve-1)	im	Zellkulturüberstand	von	
transgenen	U937	Zellen	nachweisen.	sLyve-1	wird	in	Makrophagen	und	Endothel-
zellen	 in	 ähnlicher	Weise	 durch	Metalloproteinase	 vermitteltes	 Shedding	 pro-


















11 .  INTRODUCTION
1.1 Macrophages











function	of	 tissue-specific	macrophages	 (histiocytes)	 led	 to	 the	 introduction	of	

















of	 erythrocytes	 and	 so-called	primitive	macrophages,	which	develop	without	 a	
21.  Introduction
monocytic	 intermediate.	During	 a	 second	wave	of	haematopoiesis,	 erythromye-
loid	(EMP)	and	lymphoid-myeloid	progenitors	emerge	in	the	YS.	After	the	estab-
lishment	of	blood	circulation,	 EMP	 seed	 the	 fetal	 liver	 and	 further	 tissues.	 Sub-





















































described	 in	 the	 following.	Bone	marrow	osteoclasts	 are	multinucleated	macro-
phage-derived	 cells	which	 are	 involved	 in	 bone	 remodelling	 processes	 [12].	 So	
called	alveolar	macrophages	are	located	in	the	lungs	where	they	are	exposed	to	
the	alveolar	lumen.	Besides	phagocytosis	and	clearance	of	inhaled	particles,	these	
macrophages	 also	 recycle	 surfactant	molecules	 of	 epithelial	 cells	 [13].	 The	 sinu-






to	 ensure	 tolerance	 to	 gut	flora	 and	 food	 [16].	 In	 second	 lymphoid	 tissues	 too,	
heterogeneous	populations	of	macrophage	subsets	can	be	found,	like	lymph	node	













Pathogen recognition Macrophages	 express	 numerous	 invariable	 pattern-	





receptors,	 membrane-bound	 signalling	 receptors	 or	 cytosolic	 signalling	 recep-
tors	[18].	The	recognition	of	cytosolic	pathogens	is	mediated	by	intracellular	PRR,	















cytes	which	 are	 characterized	by	 a	high	phagocytic	 capacity	 and	efficiency	due	
to	expression	of	numerous	phagocytic	receptors.	By	phagocytosis,	macrophages	




















actions	 leads	 to	 a	 pro-inflammatory	 phenotype,	 whereas	 complement-receptor	
mediated	phagocytosis	is	rather	non-inflammatory	[25].	Phagocytosis	is	a	funda-
mental	mechanism	of	the	microbicidal	activity	of	macrophages.
Pathogen-receptor	 interactions	 further	 increase	 the	 defensive	 properties	
of	macrophages	by	 stimulating	 the	production	of	microbicidal	 agents	 like	 reac-













chemotaxis  Macrophages	 play	 an	 essential	 role	 in	 host	 defence	 as	mediators	
of	innate	immunity.	However,	in	many	infections	the	number	of	tissue-resident	
macrophages	is	insufficient	to	overcome	the	pathogenic	burden.	Activated	tissue-	
resident	 macrophages	 produce	 chemoattractant	 cytokines	 in	 order	 to	 recruit	
blood	 stream	 circulating	 monocytes	 to	 the	 site	 of	 infection	 or	 inflammation,	
where	they	differentiate	into	distinct	subsets	of	dendritic	cell	and	macrophages.	
Monocytes	 are	 divided	 into	 two	 subsets	 according	 to	 their	 expression	 of	 sur-
face	 receptors.	 Classical	 human	monocytes	 are	 characterized	 by	 the	 expression	
of	CD14++CD16-	 (mice:	 lymphocyte	antigen	6	complex;	Ly6Chigh	monocytes)	and	
are	rapidly	recruited	to	the	inflammatory	site	by	chemotaxis	[27].	A	key	regulator	




Recruitment	of	phagocytes	 from	 the	blood	 stream	 requires	 transendothelial	
migration,	 a	 process	 also	 known	 as	 leukocyte	 extravasation.	 Pro-inflammatory	
cytokines	 activate	 the	endothelium	 to	express	 selectins	on	 the	 luminal	 surface	





of	 chemo	kine	 receptors	 to	 their	 corresponding	 ligands	 that	 are	present	on	 the	
endothelial	surface.	Activation	of	the	chemokine	receptor	leads	to	conformational	
changes	of	 integrins	on	monocytes,	 thus	 leading	 to	enhanced	adhesion	via	 the	
interaction	with	endothelial	intercellular	adhesion	molecule	(ICAM).	The	mono-
nuclear	phagocyte	is	now	able	to	pass	between	endothelial	cells	to	enter	the	sub-	
endothelial	 tissue	 along	 the	 chemokine	 gradient	 and	 begins	 to	 differentiate	
according	to	the	stimuli	of	the	local	microenvironment	[18].




































1.1.3 Macrophage polarization and activation





In	 1964,	 Mackaness	 and	 colleagues	 performed	 studies	 on	 macrophage	 acti-

































M1	macrophages.	 In	 contrast	 to	 that,	 Th	2	 cytokines	 IL-4	 and	 IL-13	 and	 further	
anti-inflammatory	 agents	 like	glucocorticoids	 (GC)	 and	 IL-10	 induce	 alternative	




















To	paint	 a	more	 realistic	picture	of	 the	 in vivo	 situation	Moser	 and	Edwards	













































trating	 leukocytes	 represent	a	 further	 important	 integrant,	which	can	be	 found	
during	all	tumour	stages	[43].	First	links	between	cancer	and	inflammation	were	
already	made	 in	 the	 late	 19	th	 century,	when	Rudolph	Virchow	discovered	 that	
chronic	 inflammations	may	 promote	 tumour	 growth	 already	 pointing	 towards	
macrophages	 as	 key	 players	 of	 cancer-related	 inflammation	 [44].	 Accumulating	
evidence	by	continuative	studies	of	the	past	years	revealed	the	close	relationship	
between	local	inflammation	and	tumour	growth.	Epidemiological	studies	revealed	







The	promoting	 effects	 of	 inflammation	 to	 tumour	development	 can	be	 sub-
divided	into	intrinsic	and	extrinsic	pathway.	The	intrinsic	pathway	requires	the	


















































progression	 and	 metastasis	 as	 providers	 of	 angiogenic,	 anti-inflammatory	 and	
matrix	remodelling	factors	[56].	The	important	tumour	supportive	functions	of	
macrophages	are	reflected	by	the	findings	that	in	many	different	cancers	high	TAM	
density	 correlates	with	poor	patient	prognosis	 [57,	 58].	 In	melanoma	 for	 exam-
ple	significantly	increased	numbers	of	TAM	have	been	found	in	thick	melanomas	




























functions	 of	macrophages	 by	 ablation	 of	 IL-10	 or	 its	 downstream	 target	 signal	
transducer	and	activator	of	transcription	3	(STAT3)	supports	the	generation	of	a	




deletion	of	 inhibitor	of	NFκB	kinase	 subunit	β	 (IKKβ)	and	 thus	 impaired	NFκB	
signalling	in	LysM+	myeloid	cells	in	a	murine	mouse	model	of	colitis-associated	
cancer	led	to	significant	reduction	of	tumour	size	[72].	In	the	course	of	immuno-
editing,	 tumour	 cells	 create	 an	 anti-inflammatory	 environment	by	 secretion	of	
anti-inflammatory	cytokines	like	IL-4	and	TGF-β	that	promotes	M1	/	M2	transition	
thus	in	developed	solid	tumours	macrophages	are	trophic	M2-like.
In	 tumours	 discrete	 TAM	 subpopulations	 with	 site	 specific	 functions	 exist.	




















1.3.1 Tumour progression and angiogenesis
An	essential	event	during	the	conversion	from	benign	to	malignant	in	the	course	






































1.3.2 tam promote tumour growth
As	already	described	 above,	 the	majority	of	 tumours	benefits	 from	macrophage	
infiltration	 as	 TAM	 support	 tumour	 growth,	 angiogenesis	 and	 the	 formation	of	
metastasis.	TAM	secrete	a	broad	array	of	different	mediators	which	create	a	tumour	
promoting	microenvironment,	 like	e.	g.	 IL-10	and	TGF-β.	TAM	derived	 IL-10	pre-
vents	 the	 production	 of	 pro-inflammatory	 cytokines	 in	 an	 autocrine	 manner	
fostering	 an	 immunosuppressive	 microenvironment	 and	 promotes	 an	 alterna-
tive	 activation	 profile	 in	 TAM.	 In	 addition,	 IL-10	 is	 involved	 in	 the	 differentia-










phage	recruitment,	 the	chemokine	also	promotes	Th	2-responses	which	 in	 turn	
induce	M2-like	polarization	of	TAM	[88].	TAM	are	also	an	important	source	of	the	
growth	factors	PDGF	and	VEGF,	which	promote	tumour	growth	by	inducing	tumour	










TAG2	 (RT2)	mouse	model	 of	 pancreatic	 islet	 cell	 cancer,	Gocheva	 et	 al.	 demon-




1.3.3 tam promote metastasis






















soil’	 in	which	he	 proposed	 that	 a	 pro-tumoural	microenvironment	 is	 requisite	









1.3.4 tam as targets in cancer immunotherapy
Recent	research	and	substantiated	knowledge	of	tumour	immunology	have	high-
lighted	 the	 significant	contribution	of	 smouldering	 inflammation	and	 immune	
cells,	especially	of	TAM	to	tumour	initiation,	progression	and	metastasis,	thus	TAM	
have	evolved	to	interesting	new	targets	in	adjuvant	cancer	therapies.	TAM	directed	
anti-cancer	 therapies	 rely	 principally	 on	 TAM	depletion,	 blocking	 of	monocyte	
recruitment	and	strategies	to	re-educate	TAM	towards	a	tumouricidal,	pro-inflam-
matory	phenotype.	
A	promising	 strategy	 to	 target	 specific	 cell	 populations	 is	 the	 immunotoxin	
therapy	of	cancer.	The	directed	depletion	of	TAM	is	achieved	by	coupling	of	toxins	







depletion.	Non-resorptive	ZA	 is	 actively	 taken	up	by	phagocytes	by	fluid-phase	


























model	of	pancreatic	 cancer	 treatment	with	 the	CD40	directed	mAB	 resulted	 in	
enhanced	 expression	of	MHC	 class  II	 in	macrophages	 and	 serum	 levels	 of	 pro-	
inflammatory	 cytokines	 IL-12,	 TNF-α	 and	 IFN-γ	were	 increased,	 subverting	 the	
immunosuppressive	 tumour	 microenvironment.	 Furthermore,	 therapeutic	 effi-
cacy	could	be	demonstrated	 in	patients	 suffering	 from	pancreatic	ductal	 adeno-
carcinoma	when	 the	 antibody	was	 administrated	 in	 combination	with	 gemcita-
bine	increasing	the	time	period	of	progression	free	survival	and	overall	survival	
rates	 [105].	 NFκB	 activation	 in	 macrophages	 induces	 a	 pro-inflammatory	 gene	
expression	profile.	Several	strategies	aim	at	TLR	mediated	activation	of	NFκB	in	











and	 Phase  II	 clinical	 trials.	 The	 multikinase	 inhibitor	 Sorafenib,	 which	 is	 an	
approved	drug	for	renal	cell	carcinoma	and	hepatocellular	carcinoma,	acts	on	the	









In	 summary,	 lots	 of	 strategies	 to	 prevent	 tumour	 supporting	 functions	 and	
to	eliminate	TAM	have	been	successfully	developed.	The	relevance	of	these	adju-
vant	therapies	is	illustrated	by	the	findings	that	TAM	can	influence	the	response	
to	 chemotherapeutics	 by	 counteracting	 chemotherapy	 induced	 tumour	damage	
through	misdirected	 tissue	 repair	mechanisms	 thus	 supporting	 tumour	growth	
during	 treatments	 [111].	 Hence,	 targeting	 TAM	 might	 positively	 influence	 the	
responsiveness	to	classical	anti-cancer	therapies.
1.4 Lymphatic vessel endothelial hyalu- 
ronan receptor (Lyve-1)




















membrane	proximal	 region	 [112-114].	Northern	 blot	 analysis	 and	 immunohisto-
logical	staining	revealed	abundant	Lyve-1	expression	in	spleen,	lymph	nodes,	heart,	
lung	and	fetal	liver,	as	well	as	moderate	expression	levels	in	appendix,	bone	mar-










murine	 tumour	 and	wound	 healing	models	 a	 subpopulation	 of	 F4	/	80+,	 CD11	b+	
macrophages	had	been	discovered	to	express	Lyve-1.	In vitro,	Lyve-1	expression	was	
induced	in	murine	bone-marrow	derived	macrophages	(BMDM)	by	the	combined	





















(amino	acids	 1-169)	was	not	competent	of	HA-binding	 indicating	 that	elements	
from	the	membrane	proximal	stalk	region	are	required	for	successful	interactions	























FGF-2	stimulation	induced	LYVE-1	expression	in vitro	and	in vivo [125].
1.4.3 Processing of Lyve-1
In	an	attempt	to	determine	possible	Lyve-1	activation	stimuli	researchers	found	

















1.4.4 Lyve-1 signalling and functional implications
To	characterize	the	function	of	Lyve-1,	murine	knockout	models	have	been	gen-
erated.	Lyve-1-/- mice	display	a	normal	phenotype.	The	mice	develop	a	functional	
lymphoid	system	and	development	and	 trafficking	of	 the	 lymphocyte	subset	 is	
unperturbed	as	well.	Both	metabolism	and	levels	of	HA	in	blood	and	tissue	are	











vascular	 permeability	 [131].	While	 no	 distinct	 function	 of	 Lyve-1	 on	 HA	meta-
bolism	has	been	noticed,	stimulation	with	low	molecular	weight	HA	(LMW-HA)	























1.4.5 Lyve-1 expression in tam
In	 the	 past	 years,	 research	 in	 the	 field	 of	 tumour	 associated	macrophages	 has	
revealed	their	tumour	promoting	effects	making	them	interesting	new	targets	in	
adjuvant	cancer	therapy.	Though	it	became	apparent	that	TAM	constitute	a	highly	




ization	of	 such	macrophage	markers.	 In	murine	models	Ms4a8a,	 Stabilin-1	 and	
also	Lyve-1	have	been	discovered	by	our	group	to	be	expressed	by	TAM	in	different	





expression	 of	 the	 three	mentioned	macrophages	markers	 between	 human	 and	
murine	 TAM.	 In	 addition,	 she	 conducted	 continuative	 experiments	 to	 examine	
the	nature	of	the	Lyve-1	expression	in	human	TAM.	Her	observations	are	the	basis	
of	this	work	and	the	results	concerning	Lyve-1	will	be	presented	in	the	following.	
Histopathological	 analyses	 of	 different	 human	 tumour	 entities	 revealed	 the	
presence	of	Lyve-1+	macrophages	in	colon	carcinoma,	ovarian	carcinoma	and	pri-
mary	melanoma.	In vitro, LYVE-1	was	induced	in	pBMC	after	7	days	of	stimulation	
with	M-CSF,	dexamethasone	and	 IL-4.	The	addition	of	 the	glucocorticoid	 recep-
tor	 (GR)	 antagonist	 mifepristone	 to	 the	 stimulation	 cocktail	 suppressed	 induc-






murine	macrophage	 cell	 line	RAW	264.7	 and	a	human	analogous	 cell	 line	U937	
were	 genetically	 engineered	 to	 express	 Lyve-1	 to	 analyze	 protein	 processing	 of	
Lyve-1	 in	more	detail.	By	 immunoblot	 analysis	 a	 shorter	version	of	Lyve-1	was	





shedding	 inducer	 APMA	 led	 to	 accumulation	 of	 the	 55	kDa	 Lyve-1	 form	 in	 the	
cell	culture	supernatant,	while	in	the	cell	lysates	the	amount	of	full	length	Lyve-1	







1.5 Aims of the study
We	 and	 others	 were	 able	 to	 demonstrate	 that	 Lyve-1	 expression	 is	 in	 fact	 not	


































































Reverse	 transcription	 was	 performed	 at	 42°C	 for	 60	min	 followed	 by	 heat	
induced	inactivation	of	the	enzyme	at	70°C	for	10	min.	cDNA	samples	were	stored	
at	-20°C.



















































the	fluorescent	dye	 the	master	mix	 contains	buffer,	dNTPs	 and	 a	 thermostable	
hot-start	DNA	polymerase.	The	PCR	was	run	under	standard	conditions	with	an	
MX3000P	sequence	detection	system	(Stratagene).	
2.1.4 Protein isolation and modified Lowry assay













































phide-bridges,	 SDS	 leads	 to	denaturation	of	 the	protein	and	a	constant	relation	
















branes	were	 incubated	with	 the	desired	primary	antibodies	diluted	 in	5	%	milk	











































For	 deglycosylation	 total	 cell	 lysates	were	 obtained	 from	Lyve-1+	 transgenic	
cells	lines.	The	digest	was	performed	with	the	EDEGLY	enzymatic	protein	degly-
cosylation	kit	(Sigma-Aldrich),	which	includes	the	following	proteins:	PNGase F,	
O-Glycosidase,	 α-(2 → 3,	6,	8,	9)-Neuraminidase	 (Sialidase	 A),	 β-(1 → 4)-Galactosi-
dase	and	β-N-Acetylglucosaminidase.	The	digest	was	performed	according	to	the	
manufacturer’s	instructions	at	37°C	for	3	h.










































































































300	µL	 FACS	 surface	 buffer	 and	 analyzed	with	 FACS-Canto™	II	 (BD	Biosciences)	
and	data	was	analyzed	using	FlowJo	V	10.1	software.
2.1.15 Detection of reactive oxygen species and nitric oxygen species
CD14+	 cells	 were	 stimulated	 for	 seven	 days	 either	 with	 M-CSF	 or	 M-CSF	/	dexa-	





































STEP TEMPERATURE TIME CYCLES




Final	extension 72°C 5	min 1
The	 obtained	 PCR	 product	 was	 purified	 with	 the	 aid	 of	 purification	 kit	 omni-







































2.2 In vitro assays
2.2.1 Cell culture methods







2.2.2 Human cell lines
1. u937 (atcc® crl-1593.2™)	 The	 monocytic	 cell	 line	 was	 established	 from	
malignant	cells	which	were	derived	from	a	caucasian	male	patient	suffering	from	
histiocytic	 lymphoma.	 The	 cells	 were	 cultured	 in	 RPMI-1640	 Medium	 supple-
mented	with	10	%	fetal	calf	 serum	(FCS),	 100	U	Penicillin,	as	well	as	 100	μg	/	mL	
Streptomycin	(Pen	/	Strep)	(RPMI	Complete).	As	the	cells	grow	in	suspension,	cul-


















4. 293t/17 [hek 293t/17] (atcc® crl-11268™)  The	 cells	 originate	 from	 fetal	






pyruvate.	Subcultivation	was	achieved	by	 trypsin	 treatment,	 as	described	above.	
The	splitting	ratio	was	1	:	4	to	1	:	8.
5.  human  umbilical  vein  endothelial  cells  (huvec;  Promocell  heidelberg) 
Human	primary	cells	are	isolated	from	the	vein	in	the	umbilical	cord.	The	adher-































cryo-vials	were	put	 into	 isopropanol	 insulated	 freezing	 containers,	which	were	







2.2.5 Isolation of cd14+ cells from human peripheral blood
Buffy	coat	samples	from	healthy	donors	were	obtained	from	German	Red	Cross	














cells	do	not	penetrate	 the	biocoll	 layer,	 so	 that	 a	 concentrated	band	consisting	
of	lymphocytes,	monocytes	and	thrombocytes	appears	right	between	the	biocoll	
layer	and	the	uppermost	layer	which	is	the	blood	plasma.











MACS	 (magnet	 associated	 cell	 sorting)	buffer	 and	 labelled	 for	 20	min	with	mag-

























2.2.6 Production of lenti virus for transduction of eukaryotic cells
Lenti	viruses	are	a	subset	of	retroviruses	which	are	derived	from	HIV-1.	The	advan-
tage	 of	 lentiviral	 vectors	 is	 their	 ability	 to	 transduce	 both	 dividing	 and	 non-	
dividing	cells.	Moreover,	the	transduction	of	cells	results	in	the	integration	of	the	
transgene	into	the	host	genome	and	thus	stable	expression	is	achieved.







growth	medium	 which	 supports	 plasmid	 uptake	 by	 HEK293	/	T17	 cells.	 On	 the	









2.2.7 Production of transgenic cell lines
The	lentiviral	vector	system	was	used	for	production	of	eukaryotic	transgenic	cell	





































































2.3 In vivo experiments
2.3.1 Mouse Models
C57BL	/	6	wild	 type	mice	were	purchased	from	Elevisier	 Janvier,	Le	Genest	Saint	
Isle,	 France.	 B6.129P2-Lyz	2tm1(cre)Ifo/J	 (also	 known	 as	 LysMcre)	 and	 B6.129S1-	
Lyve-1tm1Lhua/J	(Lyve-1-/-)	were	purchased	from	the	Jackson	Laboratory.	GRflox	mice	
were	provided	by	Prof.	Dr.	Günther	Schütz	[199].	
All	 mice	 are	 housed	 under	 specific	 pathogen-free	 conditions	 at	 the	 animal	
facility	Mannheim.	All	animal	experiments	were	filed	at	the	local	authorities	Regi-
erungspräsidum	Karlsruhe	under	the	numbers	G213	/	12,	G42	/	14	and	G119	/	15.
2.3.2 Murine tumour models












2.3.3 In vivo imaging
To	monitor	tumour	growth	in vivo	imaging	was	performed.	150	µL	of	D-Luciferin	
potassium	 salt	 30	mg	/	mL	 (Biovision)	 in	 PBS	were	 injected	 intraperitoneal	 into	
B16F10	 LUC	 tumour	 bearing	mice.	Mice	were	 anesthetized	 in	 an	 isoflurane	 gas	
chamber	and	luminescence	pictures	were	taken	three	min	after	substrate	injection	
with	IVIS	Lumina;	exposure	time	was	set	to	15	s	(PerkinElmer,	Living	Image	4.3).




















































































































































































































































































































































































4.1 Lyve-1+ macrophages are present in human melanoma
Lyve-1	has	been	found	not	to	be	expressed	exclusively	by	lymphatic	endothelial	





To	 determine	 if	 Lyve-1+	macrophages	 are	 also	 present	 in	human	melanoma,	
serial	sections	from	paraffin	embedded	specimens	were	prepared	and	stained	for	
Lyve-1,	the	pan-macrophage	marker	CD68	and	CD163,	which	is	a	marker	of	M2-like	
macrophages.	Histopathological	 analyses	 identified	 Lyve-1+	 cells	 as	 endothelial	
cells	and	macrophages.	Compared	 to	Lyve-1+ TAM	more	CD68+	 and	CD163+	TAM	
were	found	in	human	melanomas.	(Fig. 5	A).	
To	further	substantiate	the	existence	of	Lyve-1+	macrophages	in	human	mela-















4.2 Characterization of the in vitro induction 
of Lyve-1 in pbmc
4.2.1 m-csF, dexamethasone and il-4 induce a  
         M2-like phenotype of pbmc in vitro




to	M-CSF	 (M)	 treated	pBMC.	Besides	analysis	of	 the	macrophage	differentiation	
marker	 CD11	b,	 expression	 levels	 of	 the	 scavenger	 receptor	 CD163	 and	mannose	
receptor	CD206	were	evaluated,	as	their	expression	is	associated	with	a	M2-like	




stimulation	 (Fig. 6)	 In	general,	expression	analyses	on	protein	and	mRNA	 level	




cant.	However,	 a	 slight	down-regulation	of	CD11	b	was	observed	 in	MDI-treated	
pBMC.	Finally,	examination	of	HLA-DR	expression	on	the	protein	 level	by	FACS	
analysis	showed	comparable	expression	levels	in	M	and	MDI	treated	pBMC	(Fig. 6).











In	 addition,	 arginine	metabolism	 and	production	of	 ROS	 and	NOS	 in	M-CSF	
and	MDI	treated	pBMC	were	examined	by	means	of	FACS	and	qRT-PCR.	In	TAM	
and	M2-like	macrophages	arginase-1	is	up-regulated	promoting	the	hydrolysis	of	
	L-arginine	 to	 urea	 and	 ornithine,	whereas	 in	 pro-inflammatory	M1-like	macro-
phages	conversion	of	L-arginine	by	iNOS	to	NOS	is	prevailing	and	high	abundance	
of	ROS	is	characteristic.






















































Immunohistological	 staining	 of	 PFA-fixed	 cytospins	 from	 MDI	 stimulated	
pBMC	showed	that	the	addition	of	100	nM	mifepristone	efficiently	blocked	Lyve-1	



























4.2.4 Activation of p 38 maPk is relevant for LYVE-1 induction in pbmc
In	an	attempt	to	deepen	our	knowledge	about	the	in vitro	induction	of	LYVE-1,	we	
































4.2.5 Activation of p 38 maPk signalling via tgF-β  














expression,	 thus	no	 synergistic	 effect	 of	 GR	 and	p	38	MAPK	 signalling	 could	 be	
observed	 to	 this	 point.	 Moreover,	 (M-CSF	+)	TGF-β	 alone,	 were	 not	 sufficient	
to	 induce	gene	expression	of	LYVE-1  (Fig.  12	A).	After	 seven	days	of	 stimulation,	
LYVE-1	expression	could	not	be	detected,	when	dexamethasone	was	removed	from	








4.3 Functional analyses of Lyve-1 overexpression  
in U937 and B16F1



















U937	 derived	 Lyve-1	 had	 a	 protein	molecular	 weight	 of	 approximately	 70	kDa,	
whereas	the	322	AA	sequence	predicts	a	mass	of	35.2	kDa.	By	treatment	with	PNGase	
F	 and	 sialidase	A,	 post-translational	modifications	 in	 the	 form	of	 glycosylation	
could	be	removed	resulting	in	a	reduction	of	the	protein	weight	to	approximately	
65	kDa.	Digest	with	O-glycosilidase	did	not	show	any	effect	on	the	Lyve-1	protein	







4.3.2 Ligand binding does not influence proliferation rate of U937 Lyve-1
It	 has	 been	 described	 that	 in	 endothelial	 cells	 interactions	 of	 Lyve-1	with	 the	
ligands	FGF-2	and	 low	molecular	weight	hyaluronic	acid	 (LMW-HA)	 induce	cell	

































4.3.3 Overexpression of Lyve-1 in B16F1 increases adhesion  
          to fibronectin coated surfaces
For	further	 functional	analyses	 the	murine	melanoma	cell	 line	B16F1	was	trans-
duced	with	the	ADR3	expression	vector	containing	murine	LYVE-1	or	the	EV	con-
struct	as	a	control.	We	decided	to	use	this	model	for	two	reasons.	First,	in	contrast	
to	U937,	B16F1	 are	not	 suspension	cells	but	do	grow	adherently	 in	monolayers,	








For	 this	 purpose,	 a	 96-well	 plate	 was	 coated	 either	 with	 0.2	%	 gelatine	 or	
fibronectin	 (1	μg	/	mL).	 B16F1	 EV	 and	 B16F1	 Lyve-1	 were	 seeded	 and	 allowed	 to	











4.3.4 Lyve-1 overexpression does not influence migratory behaviour  





























After	 three	 hours	 of	 peroxide	 stimulation,	 no	 differences	 in	 the	 amount	 of	
surviving	cells	between	the	lineages	B16F1	EV	and	Lyve-1	respectively	have	been	















4.4 Functional implications of sLyve 
derived from macrophages
4.4.1 Identification of a soluble form of Lyve-1 in cell culture  
         supernatant of U937
























The	protein	bands	of	Lyve-1	were	broadly	 excised	 from	 the	Coomassie	 gel	 and	


























































cell	 line	 compared	 to	A375	 cells	 (1352	±	168.2	ng	/	mL)	 (Fig.  20	C).	 Taken	 together,	
these	results	indicate	that	sLyve-1	interferes	with	melanoma	cell	proliferation	by	
interacting	with	autocrine	HA	stimulation.
4.4.3 sLyve-1 is significantly elevated in blood plasma  
         of psoriasis  patients














which	were	 comparable	 to	 the	 control	 group	of	healthy	donors.	All	melanoma	
patients	 received	 a	 PD-1	 inhibitor	 treatment;	monitoring	 of	 sLyve-1	 levels	 dur-
ing	different	time	points	of	the	treatment	revealed	no	relevant	differences	in	the	
plasma	concentration	of	Lyve-1	(Fig. 21	B).	
4.5 Relevance of dexamethasone dependent proteins  
for tumour growth



























Further	 in vivo	 tumour	 growth	 experiments	were	 accomplished	with	B16F10	
LUC	cells.	These	cells	express	luciferase	derived	from	the	North	American	firefly.	
This	cell	 line	was	used	for	the	 in vivo	monitoring	of	 tumour	growth	in	C57BL	/	6	
Lyve-1-/-	and	wild	type	control	mice	by	measuring	a	bioluminescence	signal	which	
is	produced	by	the	tumour	cells	after	the	administration	of	the	luciferase	substrate	
luciferin.	 150	µL	of	D-Luciferin	potassium	salt	 (30	mg	/	mL)	 in	PBS	were	 injected	
intraperitoneal	 into	 the	B16F10	LUC	 tumour	bearing	mice.	The	mice	were	anes-
thetized	 in	 an	 isoflurane	 gas	 chamber	 and	 luminescence	 pictures	 were	 taken	
three	minutes	 after	 substrate	 injection	with	 IVIS	 Lumina	 (PerkinElmer,	 Living	
Image 4.3).





























4.5.2 Myeloid specific depletion of the glucocorticoid receptor  
         accelerates tumour growth
The	 in vitro	experiments	have	highlighted	the	central	role	of	glucocorticoids	for	
the	induction	of	Lyve-1.	To	define	the	role	of	glucocorticoids	for	Lyve-1	expres-
































expression	 in	 TAM.	 Evident	 differences	 regarding	 distribution	 and	 quantity	 of	
CD68+	/	Lyve-1+	 cells	 between	 tumours	 from	 control	mice	 and	 the	mutant	mice	
strain	were	not	observed	(Fig. 26).	Although,	GR	signalling	seems	to	be	a	key	reg-
ulator	of	Lyve-1	expression	in vitro,	during	tumour	growth	conditions	in vivo	other	
factors,	which	remain	 to	be	determined,	play	a	 role	 in	 the	regulation	of	Lyve-1	
expression.	 In	 summary,	 myeloid	 specific	 knockout	 of	 GR	 had	 an	 accelerating	
effect	on	tumour	growth,	but	had	no	effect	on	Lyve-1	expression	in	TAM.








5.1 Characterization of Lyve-1+ macrophages  
in vivo and in vitro
Immunohistological	 staining	 of	 human	 primary	 melanoma	 revealed	 the	 exis-
tence	of	Lyve-1+	cells	within	the	tumour	stroma	which	were	identified	by	histo-
pathological	 analyses	 as	 endothelial	 cells	 and	 macrophages.	 The	 existence	 of	
Lyve-1+	macrophages	was	further	substantiated	by	the	observation	that	these	cells	

































trol	 cells	 which	 were	 stimulated	 by	 M-CSF	 only.	 The	 expression	 levels	 of	 pan-	
macrophage	marker	CD11	b,	mannose	 receptor	CD206,	 scavenger	 receptor	CD163	
and	MHC	class II	protein	were	examined.	The	analysis	revealed	up-regulation	of	

































































combined	 stimulation	 with	 TCM	/	dexa	/	IL-4,	 Ms4a8a	 was	 identified	 as	 a	 novel	
marker	 of	murine	M2	macrophages.	 Examination	of	 regulatory	mechanisms	of	
Ms4a8a	expression	 in vitro	 revealed	 that	 impairment	of	either	GR,	p	38	MAPK	or	
NFκB	 signalling	 inhibited	Ms4a8a	 expression.	 In	 analogy	 to	 these	observations	
the	eventual	contribution	of	these	signalling	pathways	on	Lyve-1	induction	was	














p	38	 MAPK	 signalling	 has	 also	 been	 identified	 to	 be	 involved	 in	 IL-4	 medi-
ated	differentiation	of	M2	macrophages.	The	first	stimuli	which	were	identified	
to	 induce	 alternative	 activation	 of	 macrophages	 were	 IL-4	 and	 IL-13	 inducing	
enhanced	expression	of	CD206	and	diminished	expression	of	pro-inflammatory	
cytokines.	 Classically,	 IL-4	 binding	 to	 its	 corresponding	 receptor	 activates	 the	
JAK	/	STAT6	pathway	or	PI3KC	downstream	signalling.	In	murine	peritoneal	macro-
phages,	activation	of	p	38	MAPK	signalling	in	response	to	IL-4	stimulation	has	been	
observed	and	was	related	 to	 the	expression	of	M2	marker	genes,	 such	as	ARG-1,	
YM-1	and	FIZZ-1	[149].	Further	evidence	for	this	connection	was	provided	by	the	
description	of	p	38	MAPK	dependency	of	APRIL	induction	in	murine	macrophages	
following	exposure	 to	 IL-4	 [150].	 In	human	pBMC,	 stimulation	with	M-CSF	and	







5.3 Functional implications of Lyve-1 expression
Both	MDI-induced	pBMC	and	 transgenic	U937	express	Lyve-1	 in	a	highly	glyco-
sylated	form.	In	the	area	of	the	link domain	two	sites	for	N-linked	glycosylation	
have	 been	 identified	which	 are	 involved	 in	 the	 HA-binding	 capacity	 of	 Lyve-1.	









































































transfected	 control	 cells.	Hence,	 cell	migration	was	 not	 influenced	 directly	 by	
Lyve-1	overexpression.	However,	a	possible	role	of	Lyve-1	in	chemotaxis	induced	
migration	should	not	be	disregarded	and	needs	further	evaluation.	
Both	 signalling	 pathways	 identified	 to	 be	 relevant	 for	 the	 in vitro	 induction	
of	Lyve-1	are	regulators	of	cell	survival.	Glucocorticoids	are	widely	used	 in	can-
cer	therapies	based	on	their	apoptosis	promoting	effect	on	cancer	cells.	However,	








5.4 Processing of Lyve-1
The	high	sequence	homology	of	Lyve-1	and	CD44	imply	possible	functional	sim-
ilarities	between	the	HA-receptors	at	least	to	some	extent.	CD44	is	a	type	I	trans-
membrane	 protein	 which	 is	 expressed	 almost	 ubiquitously	 in	 malignant	 and	
benign	cells	with	diverse	 functions	mediating	proliferation,	differentiation	and	
migration.	 Interactions	with	HA	and	 further	 ligands	 such	as	osteopontin,	 colla-
















tional	proteases	 involved	 in	 shedding	of	CD44.	The	 residual	C-terminal	part	of	
CD44	 experiences	 further	 proteolytic	 processing.	 Intramembranous	 cleavage	 by	














binding	 to	 its	 corresponding	 receptor	 VEGFR-2	 induced	 ERK-dependent	 activa-
88
5.  Discussion
tion	 of	 ADAM17	which	 in	 turn	 cleaved	 Lyve-1.	 In	 a	migration	 assay	 it	 was	 fur-
ther	demonstrated	that	VEGF-A	induced	shedding	of	Lyve-1	promoted	migration	
of	LEC	across	HA-coated	membranes	[128].	The	second	study	demonstrated	MT1-













































In	 this	 context,	 our	 results	 demonstrated	 that	macrophage	 derived	 sLyve-1	
























Under	 physiological	 conditions	 soluble	 CD44	 (sCD44)	 has	 been	 detected	 in	























to	 hyperkeratosis	 and	 parakeratosis.	 In	 psoriatic	 lesions	 the	 number	 of	 mono-
nuclear	leukocytes	is	significantly	increased	and	abnormal	vascularization	leads	to	
the	development	of	numerous	dilated	dermal	blood	vessels	resulting	in	erythema.	











MMP	 expression	 has	 been	 associated	 with	 melanoma	 progression	 [179].	 There-
fore,	it	is	also	conceivable	that	extensive	shedding	indeed	occurs	during	tumour	
























5.5 Lyve-1 deficiency promotes tumour growth














Surprisingly,	 we	 detected	 enhanced	 tumour	 growth	 of	 B16	 transplanted	
tumours	in	Lyve-1	knockout	mice.	As	we	and	others	identified	a	soluble	form	of	
Lyve-1	which	can	be	secreted	by	endothelial	cells	and	macrophages,	we	speculate	
that	excessive	production	of	sLyve-1	 impairs	 tumour	growth	 in	wild	 type	mice.	
Shedding	 of	 the	 ectodomain	 of	 cell	 surface	 receptors	 can	 have	 diverse	 effects.	












gain	a	better	understanding	of	 the	distinct	 functions	of	 full	 length	and	soluble	
Lyve-1	for	tumour	growth,	differential	expression	of	the	protein	forms	in	a	tumour	
model	would	be	necessary.	
Therefore,	 it	 should	not	be	disregarded	 that	our	Lyve-1-/-	model	 results	 in	 a	
global	knockout	of	Lyve-1	expression	such	that	obstruction	of	Lyve-1	expression	
is	not	restricted	to	macrophages	but	affects	the	whole	organism	and	hence	also	
lymphatic	 endothelial	 cells.	Characterization	of	Lyve-1	null	mice	 revealed	mor-
phological	and	functional	changes	 in	the	lymphatic	vessels	marked	by	constitu-
tive	 increased	 interstitial	 fluid	flow	 [130].	Various	 studies	highlight	 the	 critical	
involvement	of	the	lymphatics	in	tumour	growth	and	progression,	not	only	as	a	
possible	 route	 for	 tumour	 dissemination.	 The	 lymphatic	 vessel	 network	 consti-
tutes	 the	 second	 circulatory	 system	which	 collects	 interstitial	 fluid	 and	macro-
molecules,	 which	 constantly	 leak	 from	 blood	 vessels,	 and	 transport	 it	 back	 to	
the	blood	vasculature.	Under	physiological	 conditions,	 the	 lymphatic	 system	 is	
involved	in	tissue	fluid	homeostasis,	immune	surveillance	and	fat	absorption.	Spa-
tial	 restriction	 during	 the	 expansion	 of	 the	 tumour	mass	 leads	 to	 the	 develop-
ment	of	high	intratumoural	pressure.	Simultaneously	the	amount	of	 interstitial	





































impaired	 resolution	of	 the	 inflammatory	 innate	 immune	 response	 the	 	GRLysMcre	
mouse	showed	greater	mortality	when	being	challenged	with	LPS.	Mechanistically,	
GR	deficiency	led	to	impaired	inhibition	of	MAPK	signalling	following	LPS	medi-






















While	 in vitro	Lyve-1	 induction	was	crucially	dependent	on	GR	signalling	we	











completely	 within	 the	 Lyve-1	 knockout	 model,	 as	 the	 global	 knockout	 affects	
expression	of	Lyve-1	also	in	the	lymphatic	vasculature	and	thus	our	findings	can-
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